Hematologic Malignancies Market is estimated to be US$ 159.6 billion by 2032 with a CAGR of 12.6% over the forecast period (2022-2032)

Download Sample

Published Date: December 2022

Hematologic Malignancies are blood cancers and fifth most common type of cancer group in developed regions of the world. Chemotherapy is the use of anti-cancer drugs which are injected into vein, under the skin, or into CSF (cerebrospinal fluid), or drugs that are taken by mouth to control or destroy the cancer cells. Chemotherapy is the important treatment for patient with acute myeloid leukemia. Treatment for acute myeloid leukemia is divided into various phases like, Induction Phase – first phase of treatment which is short & intensive and last about a week. The goal of induction is to clear blood of leukemia cells and reduce the number of blasts in bone marrow to become normal. Consolidation Phase – a chemo given after patient is recovered from induction phase. Chemo is given for killing small number of leukemia cells which are still around & cannot be seen. Chemo is given in cycles for consolidation. Maintenance Phase (post-consolidation) – It involves giving low dose of chemo for months or years after consolidation phase is finished and often used in treating acute promyelocytic leukemia. Chemo drugs like Cytarabine and Anthracycline drug such as Daunorubicin are most often used in treatment of acute promyelocytic leukemia. Immunotherapy has proven for improving overall survival rate in cancer patients. Immunotherapy has shown massive clinical success against hematologic malignancies. Immunotherapies like T-cell immunotherapy, non-myeloablative transplantation, natural killer cells, T-cell immunotherapy, immune against to monoclonal antibodies & vaccination is used in treating hematological malignancy. However, rising prevalence of cancer disease has fueled the target market growth.

The report “Hematologic Malignancies Market, By Type (Lymphoma, Leukemia, Multiple Myeloma), By Therapy (Radiotherapy, Chemotherapy, Immunotherapy), By End-Users (Hospitals, Homecare, Specialty Clinics, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Key Highlights:

In August 2022, Novartis ‘Scemblix’ is approved by European Commission for adult patients with chronic myeloid leukemia (CML). Newly developed Scemblix has become the first chronic myeloid leukemia treatment in Europe which works specifically by targeting ABL myristol pocket by offering reimagined treatment approach for patients experiencing intolerance & resistance to currently available TKI therapies.
In November 2021, Pfizer Inc., has announced the successful completion of acquisition of Trillium Therapeutics which is a clinical stage immune-oncology company that develops innovative therapies for treating cancer. This acquisition has combined Pfizer’s research & global development capabilities with Trillium’s innovative discoveries that allows for accelerating breakthrough that change patient lives by developing therapies in hematological malignancies and other types of cancer.

Analyst View:

The key factor driving the growth of the Hematologic Malignancies market is rising prevalence of blood cancer diseases and rapid growth of urban population. Urbanization has given rise in smoking and alcohol intake which has led to cancer diseases. Various advanced therapies like monoclonal antibody therapy has revolutionized cancer treatment by significantly improving patient survival in hematologic malignancies and solid tumors. Technological advancement has increased the effectiveness of immunotherapy. Radio-immunotherapy has proven effectiveness in hematologic malignancies. Continued research & development for improving components of ICs which includes linker optimization & development of more potent, specific effector molecules may expand and be used further in various hematologic cancers. Research & development is highly recommended to identify new precise molecular targets & pathways for reducing damage of normal cells and associated side-effects. However, rising prevalence of blood cancer diseases and advancement in therapies is expected to boost the demand for Hematologic Malignancies market growth over the forecast period. As a result, market competition is intensifying, and both big international corporations and start-ups are vying to establish position in the market.

Browse 60 market data tables and 35 figures* through 140 slides and in-depth TOC on* “Hematologic Malignancies Market, By Type (Lymphoma, Leukemia, Multiple Myeloma), By Therapy (Radiotherapy, Chemotherapy, Immunotherapy), By End-Users (Hospitals, Homecare, Specialty Clinics, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Hematologic-Malignancies-Market-5023

Key Market Insights from the report:

Hematologic Malignancies Market accounted for US$ 54.2 billion in 2022 and is estimated to be US$ 159.6 billion by 2032 and is anticipated to register a CAGR of 12.6%. The Hematologic Malignancies Market is segmented based on Type, Therapy, End-Users and Region.

Based on Type, Hematologic Malignancies Market is segmented into Lymphoma, Leukemia, Multiple Myeloma.
Based on Therapy, Hematologic Malignancies Market is segmented into Radiotherapy, Chemotherapy, Immunotherapy.
Based on End-Users, Hematologic Malignancies Market is segmented into Hospitals, Homecare, Specialty Clinics, and others.
By Region, the Hematologic Malignancies Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Competitive Landscape & their strategies of Hematologic Malignancies Market:

The prominent players operating in the Hematologic Malignancies Market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

Explains an overview of the product portfolio, including product development, planning, and positioning
Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
Detailed analysis of the market revenue over the forecasted period.
Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
Study on the segments that are anticipated to dominate the market.
Study on the regional analysis that is expected to register the highest growth over the forecast period